Back to search results

Improving Oral Medication Adherence in Cancer Patients

This study at Einstein Medical Center is looking at ways to help cancer patients better take their oral chemotherapy medications. Many patients in this area have diverse backgrounds, may have difficulty reading, and face financial challenges, which can make it harder to stick to their medication schedule. The study will compare standard education (information about chemotherapy drugs and side effects) with an enhanced education and support program. We want to see if these interventions improve how well patients take their oral chemotherapy over 6 months. You might be able to join if you are an adult with certain types of stage III or IV cancer and are taking oral chemotherapy agents. The study aims to enroll 110 participants.

Study design
This is an interventional study planning to enroll 110 participants. It will compare standard care with an enhanced education and support intervention.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Adherence to oral chemotherapy will be measured at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03245411

Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients

Recruiting
NAAges 18+Interventional
Thomas Jefferson University
~110 participants
Updated 2026-05-29 on ClinicalTrials.gov
What's tested:Intervention

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adherence to oral chemotherapy
Measured over 6 months

Conditions

Cancer

Explore related trials

Breast CarcinomaChronic Lymphocytic LeukemiaChronic Myeloid Leukemia, BCR-ABL1 PositiveColorectal CarcinomaGastrointestinal Stromal TumorHepatocellular CarcinomaLung Non-Small Cell CarcinomaMelanomaMultiple MyelomaMyelodysplastic SyndromeMyelofibrosisMyeloproliferative disorderOvarian CarcinomaProstate CarcinomaRenal Cell Carcinoma

NCT03245411

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Albert Einstein Healthcare Network

    Philadelphia, Pennsylvaniastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Claudia M Dourado, MD · PRINCIPAL_INVESTIGATOR · Thomas Jefferson University

Who to contact

Claudia M Dourado, MD
[email protected]
215-456-3880
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All patients on oral chemotherapeutic agents
Clinical diagnosis of stage IV breast cancer
Clinical diagnosis of stage III and IV colorectal cancer (not receiving concurrent radiation therapy)
Clinical diagnosis of stage IV non-small cell lung cancer
Clinical diagnosis of stage IV renal cell carcinoma
Clinical diagnosis of stage IV ovarian carcinoma
Clinical diagnosis of multiple myeloma
Clinical diagnosis of chronic myelogenous leukemia on TKI
Clinical diagnosis of myelodysplastic syndrome on Lenalidomide
Adjuvant treatment for Gastro Intestinal Stromal Tumor
Clinical diagnosis of chronic Lymphocytic Leukemia
Clinical diagnosis of metastatic Prostate cancer
Clinical diagnosis of hepatocellular Carcinoma
Clinical diagnosis of stage IV Melanoma
Clinical diagnosis of myelofibrosis/myeloproliferative neoplasms
Age \>18 years
ECOG Performance Status \<3

Exclusion

ECOG Performance Status of 3 and above
Concurrent chemo radiation
Non-English speaker
Clinical diagnosis of dementia, or otherwise unable to give informed consent.
History of non-compliance (defined as the history of 2 or more missed appointments in the clinic).
Pregnant patients
Nursing Home Patients
Incarcerated

What this trial measures

  • Adherence to oral chemotherapy6 months

    Frequency of missed chemotherapy doses post randomization (based on interviews)